Brainstorm Cell Therapeutics COO David Setboun resigns effective May 31, 2023

BRAINSTORM CELL THERAPEUTICS INC.

David Setboun, PhD, MBA, EVP and COO, notified resignation on May 18, 2023.
Resignation effective May 31, 2023; he is leaving to pursue another opportunity.
Dr. Setboun's decision was not due to any disagreement with the company's operations, policies, or practices.
BCLI has not announced a replacement for the COO role.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David Setboun

Chief Operating Officer

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

Effective: 2023-05-31
Filed: May 24, 2023, 7:59 PM ET

On May 18, 2023, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer of Brainstorm Cell Therapeutics Inc. (the “Company”), notified the Company of his decision to resign from his role effective as of May 31, 2023 to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David Setboun resigned as Chief Operating Officer at BRAINSTORM CELL THERAPEUTICS INC..

Action: resigned
Role: Chief Operating Officer

Exact text from the filing

On May 18, 2023, David Setboun, PhD, MBA, Executive Vice President and Chief Operating Officer of Brainstorm Cell Therapeutics Inc. (the “Company”), notified the Company of his decision to resign from his role effective as of May 31, 2023 to pursue another opportunity.

View on SEC.gov

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-064177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.